サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1784034

心的外傷後ストレス障害治療の世界市場

Post-Traumatic Stress Disorder Treatment

出版日
ページ情報
英文 274 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
心的外傷後ストレス障害治療の世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 274 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

心的外傷後ストレス障害治療の世界市場は2030年までに27億米ドルに達する

2024年に22億米ドルと推定される心的外傷後ストレス障害治療の世界市場は、分析期間2024-2030年にCAGR 3.5%で成長し、2030年には27億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗うつ薬は、CAGR 3.8%を記録し、分析期間終了時には13億米ドルに達すると予測されます。抗不安薬セグメントの成長率は、分析期間中CAGR 4.0%と推定されます。

米国市場は推定5億9,210万米ドル、中国はCAGR6.5％で成長予測

米国の心的外傷後ストレス障害治療市場は2024年に5億9,210万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを6.5%として、2030年までに5億3,350万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.7%と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界の心的外傷後ストレス障害（PTSD）治療市場- 主要動向と促進要因まとめ

PTSD治療の進歩は患者ケアをどのように形成しているか？

心的外傷後ストレス障害（PTSD）の治療状況は、医学の進歩やトラウマ関連障害に対する深い理解によって大きく進化しています。従来の治療法には、主に選択的セロトニン再取り込み阻害薬（SSRI）やセロトニン・ノルエピネフリン再取り込み阻害薬（SNRI）があり、中でもセルトラリンやパロキセチンといった薬が最も多く処方されていました。しかし、最近の画期的な進歩により、ケタミン系治療やサイケデリック支援精神療法などの代替薬理学的治療が研究されるようになり、治療抵抗性のPTSD症例で症状の急速な緩和が認められています。

また、神経生物学的研究の高まりは、PTSDがどのように脳機能を変化させるかについての理解を深め、恐怖反応や記憶の定着に関連する神経経路を調節する標的療法の開発を促進しています。薬物療法に加え、長期暴露療法、認知処理療法（CPT）、仮想現実を利用した暴露療法などの心理療法技法の進歩により、治療成績が向上しています。PTSD治療における人工知能（AI）の統合の進展は、個別化された治療法の推奨や、より良い診断と治療順守のための予測分析を可能にすることで、患者ケアをさらに変革しています。

PTSD治療の需要を牽引する消費者と市場の動向とは？

PTSDとそのメンタルヘルスへの影響に対する世界の認識の高まりは、より効果的な治療オプションに対する需要に大きく影響しています。退役軍人、第一応答者、外傷性出来事の被害者は最もリスクの高い集団のひとつであり、PTSDの研究と治療へのアクセスを支援するヘルスケアイニシアチブと資金提供プログラムのターゲットとなっています。米国退役軍人省によるメンタルヘルスサービスの拡大など、政府が支援するイニシアチブは、診断率の向上と幅広い治療の導入に貢献しています。

商業分野では、デジタル治療薬の台頭が勢いを増しており、モバイルアプリケーションや遠隔医療サービスによって、エビデンスに基づくPTSD治療への遠隔アクセスが提供されています。ストレスに対する生理的反応をモニターするウェアラブル技術もPTSD管理に不可欠な要素となっており、個人がリアルタイムで症状を追跡し緩和するのに役立っています。市場を形成するもう1つの重要な傾向は、マインドフルネスに基づくストレス軽減（MBSR）、鍼治療、食事介入など、より包括的な治療戦略のために従来の治療を補完するホリスティックで統合的な治療アプローチが好まれるようになっていることです。

PTSD治療のイノベーションをリードしている地域は？

北米がPTSD治療市場を独占しているのは、強力な研究開発活動、確立されたメンタルヘルスケアのインフラ、PTSD治療とリハビリテーションプログラムを支援する政府の好意的な政策によるものです。主要製薬企業やメンタルヘルス研究機関の存在が、この地域における新規治療薬の開発を加速させています。特に米国では、PTSD関連の臨床試験への投資が増加しており、サイケデリック補助療法やケタミンを用いた治療法の画期的な進歩が規制当局の注目を集めています。

欧州もこれに続き、ドイツ、英国、フランスなどの国々が、PTSDやその他のトラウマ関連障害に対処するための大規模なメンタルヘルスプログラムを実施しています。欧州医薬品庁（EMA）は、PTSD治療の標準を高めるため、新薬の処方や治療プロトコルを積極的に評価しています。一方、アジア太平洋地域は、メンタルヘルスに対する意識の高まり、ヘルスケアインフラの拡大、紛争や自然災害、職業的トラウマの影響を受けた人々の間でPTSD有病率が増加していることから、潜在的な成長市場として浮上しています。しかし、アジアや中東の国々では、メンタルヘルスを取り巻く文化的な偏見が依然として課題となっており、対象を絞った啓発キャンペーンや政策改革が必要となっています。

PTSD治療市場の成長はいくつかの要因によってもたらされる

PTSD治療市場の最も大きな成長促進要因の1つは、MDMA、シロシビン、ケタミンによるサイケデリック支援療法などの新規治療薬の採用が増加していることです。これらの治療法は臨床試験で有望な結果を示しており、現在進行中の規制当局による評価や、さまざまな地域での承認の可能性につながっています。バイオマーカーに基づく診断や遺伝子プロファイリングを活用した個別化医療の拡大は、PTSD患者の治療戦略をさらに最適化し、より高い有効性と副作用の軽減を確実なものにしています。

市場拡大に拍車をかけているもう一つの重要な要因は、遠隔医療とデジタルメンタルヘルスソリューションの普及です。オンラインセラピーセッション、AI主導のメンタルヘルスチャットボット、遠隔モニタリングツールの需要が急増し、特にサービスが行き届いていない地域でPTSD治療がより身近なものになっています。PTSD治療におけるニューロフィードバックと経頭蓋磁気刺激（TMS）の統合も、症状管理のための非侵襲的で薬物を使用しない代替手段を提供することで、市場成長に寄与しています。

さらに、企業のメンタルヘルス・プログラムや職場のストレス管理への取り組みに注目が集まっていることで、臨床現場以外でのPTSD関連治療の採用が増加しています。政府や民間企業は、従業員の健康増進プログラムに投資しており、これにはトラウマにさらされた労働者のためのメンタルヘルス・リソースやカウンセリング・サービスへのアクセスも含まれています。規制当局が革新的な治療法の承認を引き続き支援し、ヘルスケアプロバイダーがPTSDに焦点を当てたサービスを拡大していることから、市場は技術、治療、政策主導の進歩の組み合わせによって持続的な成長が見込まれます。

セグメント

薬剤クラス（抗うつ薬、抗不安薬、抗精神病薬、その他薬剤クラス別）、流通チャネル（病院薬局、小売薬局、その他薬局）

調査対象企業の例

  • Addex Therapeutics Ltd.
  • Alto Neuroscience, Inc.
  • Aptinyx Inc.
  • Atai Life Sciences N.V.
  • Beckley Psytech Limited
  • Bionomics Limited
  • Boehringer Ingelheim GmbH
  • COMPASS Pathways plc
  • H. Lundbeck A/S
  • Jazz Pharmaceuticals plc
  • Lykos Therapeutics
  • MAPS Public Benefit Corporation
  • MicroTransponder Inc.
  • MindMed（Mind Medicine Inc.）
  • Nobilis Therapeutics
  • Otsuka Pharmaceutical Co., Ltd.
  • Praxis Precision Medicines, Inc.
  • Silo Pharma Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Unitary Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32650

Global Post-Traumatic Stress Disorder Treatment Market to Reach US$2.7 Billion by 2030

The global market for Post-Traumatic Stress Disorder Treatment estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Antidepressant Drugs, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Anti-anxiety Drugs segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$592.1 Million While China is Forecast to Grow at 6.5% CAGR

The Post-Traumatic Stress Disorder Treatment market in the U.S. is estimated at US$592.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$533.5 Million by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Post-Traumatic Stress Disorder (PTSD) Treatment Market - Key Trends & Drivers Summarized

How Are Advancements in PTSD Treatment Reshaping Patient Care?

The treatment landscape for post-traumatic stress disorder (PTSD) has evolved significantly, driven by medical advancements and a deeper understanding of trauma-related disorders. Traditional treatment methods primarily included selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), with medications such as sertraline and paroxetine being among the most prescribed. However, recent breakthroughs have led to the exploration of alternative pharmacological treatments, including ketamine-based therapies and psychedelic-assisted psychotherapy, which have demonstrated rapid symptom relief in treatment-resistant PTSD cases.

The rise of neurobiological research has also led to a better understanding of how PTSD alters brain function, fostering the development of targeted therapies that regulate neural pathways associated with fear response and memory consolidation. In addition to pharmacotherapy, advancements in psychotherapy techniques, such as prolonged exposure therapy, cognitive processing therapy (CPT), and virtual reality-based exposure therapy, are improving treatment outcomes. The growing integration of artificial intelligence (AI) in PTSD treatment is further transforming patient care by enabling personalized therapy recommendations and predictive analytics for better diagnosis and treatment adherence.

What Consumer and Market Trends Are Driving Demand for PTSD Treatments?

Increasing global awareness of PTSD and its impact on mental health has significantly influenced the demand for more effective treatment options. Military veterans, first responders, and victims of traumatic events are among the highest-risk populations, leading to targeted healthcare initiatives and funding programs supporting PTSD research and treatment accessibility. Government-backed initiatives, such as the U.S. Department of Veterans Affairs' expanded mental health services, have contributed to increased diagnosis rates and broader treatment adoption.

In the commercial sector, the rise of digital therapeutics has gained momentum, with mobile applications and telehealth services providing remote access to evidence-based PTSD treatments. Wearable technology that monitors physiological responses to stress is also becoming an integral part of PTSD management, helping individuals track and mitigate symptoms in real time. Another key trend shaping the market is the increasing preference for holistic and integrative treatment approaches, including mindfulness-based stress reduction (MBSR), acupuncture, and dietary interventions, which complement conventional therapies for a more comprehensive treatment strategy.

Which Regions Are Leading in PTSD Treatment Innovations?

North America dominates the PTSD treatment market due to strong research and development activities, a well-established mental healthcare infrastructure, and favorable government policies supporting PTSD treatment and rehabilitation programs. The presence of leading pharmaceutical companies and mental health research institutions has accelerated the development of novel therapeutics in the region. The United States, in particular, has witnessed increased investment in PTSD-related clinical trials, with breakthroughs in psychedelic-assisted therapy and ketamine-based treatments gaining regulatory attention.

Europe follows closely behind, with countries like Germany, the UK, and France implementing extensive mental health programs to address PTSD and other trauma-related disorders. The European Medicines Agency (EMA) has been actively evaluating new drug formulations and treatment protocols to enhance the standard of PTSD care. Meanwhile, the Asia-Pacific region is emerging as a potential growth market due to rising mental health awareness, expanding healthcare infrastructure, and increasing PTSD prevalence among populations affected by conflict, natural disasters, and occupational trauma. However, cultural stigmas surrounding mental health in several Asian and Middle Eastern nations remain a challenge, necessitating targeted awareness campaigns and policy reforms.

The Growth in the PTSD Treatment Market Is Driven by Several Factors

One of the most significant growth drivers in the PTSD treatment market is the increasing adoption of novel therapeutics, such as psychedelic-assisted therapy with MDMA, psilocybin, and ketamine. These treatments have demonstrated promising results in clinical trials, leading to ongoing regulatory evaluations and potential approvals in various regions. The expansion of personalized medicine, utilizing biomarker-based diagnostics and genetic profiling, is further optimizing treatment strategies for individuals with PTSD, ensuring higher efficacy and reduced side effects.

Another crucial factor fueling market expansion is the proliferation of telehealth and digital mental health solutions. The demand for online therapy sessions, AI-driven mental health chatbots, and remote monitoring tools has surged, making PTSD treatment more accessible, particularly in underserved areas. The integration of neurofeedback and transcranial magnetic stimulation (TMS) in PTSD treatment is also contributing to market growth by offering non-invasive, drug-free alternatives for symptom management.

Moreover, the growing focus on corporate mental health programs and workplace stress management initiatives is increasing the adoption of PTSD-related treatments beyond clinical settings. Governments and private organizations are investing in employee wellness programs, which include access to mental health resources and counseling services for trauma-exposed workers. As regulatory agencies continue to support the approval of innovative treatments and healthcare providers expand their PTSD-focused services, the market is expected to witness sustained growth, driven by a combination of technological, therapeutic, and policy-driven advancements.

SCOPE OF STUDY:

The report analyzes the Post-Traumatic Stress Disorder Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Addex Therapeutics Ltd.
  • Alto Neuroscience, Inc.
  • Aptinyx Inc.
  • Atai Life Sciences N.V.
  • Beckley Psytech Limited
  • Bionomics Limited
  • Boehringer Ingelheim GmbH
  • COMPASS Pathways plc
  • H. Lundbeck A/S
  • Jazz Pharmaceuticals plc
  • Lykos Therapeutics
  • MAPS Public Benefit Corporation
  • MicroTransponder Inc.
  • MindMed (Mind Medicine Inc.)
  • Nobilis Therapeutics
  • Otsuka Pharmaceutical Co., Ltd.
  • Praxis Precision Medicines, Inc.
  • Silo Pharma Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Unitary Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Post-Traumatic Stress Disorder Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Recognition of Post-Traumatic Stress Disorder as a Critical Mental Health Condition Drives Treatment Demand
    • Increasing Awareness of PTSD Symptoms and Impact Spurs Growth in Therapeutic Solutions
    • Expansion of PTSD Diagnosis and Screening Initiatives Expands Addressable Market for Treatment Options
    • Advancements in Psychotherapy and Cognitive Behavioral Therapy Drive Adoption of New PTSD Treatment Modalities
    • Rising Incidence of PTSD in Veterans and First Responders Accelerates Demand for Specialized Treatments
    • Development of Digital Therapeutics and Mobile Applications for PTSD Treatment Strengthens Market Outlook
    • Growing Investment in PTSD Research and Clinical Trials Fosters Innovation in Treatment Options
    • Integration of Telemedicine and Remote Counseling Services Enhances Accessibility to PTSD Care
    • Increased Focus on Personalized and Patient-Centric PTSD Treatment Solutions Expands Market Opportunity
    • Emerging Role of Psychedelic-Assisted Therapy and Ketamine in PTSD Treatment Generates Demand for Alternative Therapies
    • Growing Global Prevalence of Trauma Exposure Fuels Market Growth for PTSD Treatment Solutions
    • Mental Health Stigma Reduction Efforts Propel Public Willingness to Seek PTSD Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Post-Traumatic Stress Disorder Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Post-Traumatic Stress Disorder Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Antidepressant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anti-anxiety Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anti-anxiety Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Anti-anxiety Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Post-Traumatic Stress Disorder Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Post-Traumatic Stress Disorder Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Post-Traumatic Stress Disorder Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Post-Traumatic Stress Disorder Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Post-Traumatic Stress Disorder Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Post-Traumatic Stress Disorder Treatment by Drug Class - Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Drug Class - Percentage Breakdown of Value Sales for Antidepressant Drugs, Anti-anxiety Drugs, Antipsychotic Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Post-Traumatic Stress Disorder Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION